Method and composition for treatment of skeletal dysplasias
The present invention discloses pharmaceutical compositions for the treatment of skeletal dysplasias, comprising as an active ingredient at least one natriuretic peptide. Unexpectedly, it has been shown that the natriuretic factors may be effective for bone elongation in situations of abnormal bone growth especially for achondroplasia. The effects of the natriuretic peptide may be further enhanced by prolonging its residence time or action at the target site.
1. A pharmaceutical composition for bone elongation or treating skeletal dysplasias comprising at least one natriuretic peptide variant set forth in SEQ ID NO:5 wherein Xaa=Leu, Ile, Val; Xbb=Lys, Leu, Met; Xcc=Leu, Ile, Ala, Val; Xdd=Ser, Ala, Gly, Thr, Asn; Xee=Ala, Trp, His, Lys, Ser, Gly; Xff=Gly, Lys, Ala, Leu; and Xgg=Leu, Met, and a carrier or excipient, wherein SEQ ID NO:5 is other than amino acid sequence set forth in SEQ ID NO:2.
2. The pharmaceutical composition according to claim 1 further comprising an inhibitor of the natriuretic peptide clearance receptor.
3. The pharmaceutical composition according to claim 1 further comprising an inhibitor of the neutral endopeptidase 24.11.
4. The pharmaceutical composition according to claim 3 wherein the inhibitor of neutral endopeptidase 24.11 is thiorphan or candoxatril.
5. The pharmaceutical composition according to claim 1 further comprising an inhibitor of fibroblast growth factor receptor 3 tyrosine kinase.
6. The pharmaceutical composition according to claim 1 wherein the natriuretic peptide is fused to a carrier protein forming a natriuretic peptide-carrier protein fusion protein; wherein the carrier protein is selected from the group consisting of growth hormone (GH), insulin like growth factor-1 (1GF-1) and thyroid hormone (TH).
7. The pharmaceutical composition according to claim 6 wherein the carrier protein comprises growth hormone.
8. The pharmaceutical composition according to claim 6 wherein said at least one natriuretic peptide is conjugated to a carrier protein forming a natriuretic peptide-carrier protein conjugate.
9. A method for increasing the size of a bone growth plate in a bone comprising treating the hone in vitro with an effective amount of at least one natriuretic peptide in a pharmaceutical composition according to claim 1 .
10. The method according to claim 9 further comprising inhibiting the natriuretic peptide clearance receptor.
11. The method according to claim 9 further comprising an inhibitor of the neutral endopeptidase 24.11.
12. The method according to claim 11 wherein the inhibitor of neutral endopeptidase 24.11 is thiorphan or candoxatril.
13. The method according to claim 12 wherein the step of administering an inhibitor of neutral endopeptidase is performed simultaneously with the step of administering an effective amount of at least one natriuretic peptide.
14. The method according to claim 9 further comprising an inhibitor of fibroblast growth factor receptor 3 tyrosine kinase.
15. The method according to claim 9 wherein said at least one natriuretic peptide is fused to a carrier protein forming a natriuretic peptide-carrier protein fusion protein protein wherein the carrier protein is selected from the group consisting of growth hormone (GH), insulin like growth factor-1(1GF-1) and thyroid hormone (TH).
16. The method according to claim 15 wherein the carrier protein fusion protein comprises growth hormone.
17. The method according to claim 9 wherein said at least one natriuretic peptide is conjugated to a carrier protein forming a natriuretic peptide-carrier protein conjugate.
18. The method according to claim 9 wherein the bone is a limb bone.
19. The method according to claim 18 wherein the limb bone is an achondroplasic bone.
20. A method for elongation of bone, comprising treating the bone in vitro with an effective amount of at least one natriuretic peptide in a pharmaceutical composition according to claim 1 .
21. The method according to claim 20 further comprising inhibiting the natriuretic peptide clearance receptor.
22. The method according to claim 20 further comprising an inhibitor of the neutral endopeptidase 24.11.
23. The method according to claim 22 wherein the inhibitor of neutral endopeptidase 24.11 is thiorphan or candoxatril.
24. The method according to claim 22 wherein the step of administering an inhibitor of neutral endopeptidase is performed simultaneously with the step of administering an effective amount of at least one natriuretic peptide.
25. The method according to claim 20 further comprising an inhibitor of fibroblast growth factor receptor 3 tyrosine kinase.
26. The method according to claim 20 wherein said at least one natriuretic peptide is a natriuretic peptide fused to a carrier protein forming a natriuretic peptide-carrier protein fusion protein.
27. The method according to claim 20 wherein the carrier protein comprises growth hormone.
28. The method according to claim 20 wherein said at least one natriuretic peptide is conjugated to a carrier protein forming a natriuretic peptide-carrier protein conjugate wherein the carrier protein is selected from the group consisting of growth hormone (GH), insulin like growth factor-1(1GF-1) and thyroid hormone (TH).
29. The method according to claim 20 wherein the bone is a limb bone.
30. The method according to claim 20 wherein the limb bone is an achondroplasic bone.